18 completed, 14 active not recruiting, 13 recruiting, 5 terminated. 61 Phase 2, 3 Phase 1, 1 Phase 3.
Follow apalutamide: new trials by email Literature Review of apalutamide trials Research Report on apalutamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer. ADT plus abiraterone or other ARPIs(apalutamide, enzalutamide, rezvilutamide, darolutamide) - Metastatic Hormone-Sensitive Prostate Cancer | Phase 2 | Not yet recruiting | Anhui Medical University | 40 | 2026-10-01 | 2026-08-31 |
| Study of Oral MRT-2359 With Apalutamide in Prostate Cancer Oral MRT-2359, Apalutamide - Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Monte Rosa Therapeutics, Inc | 25 | 2026-08-18 | 2026-11-05 |
| Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients Local treatment, Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide). - Prostate Cancer Metastatic Disease | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 192 | 2025-08-01 | 2026-03-25 |
| Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer SX-682, Apalutamide - Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 78 | 2025-04-28 | 2026-09-08 |
| Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel - Metastatic Castration Sensitive Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2025-01-10 | 2026-04-01 |
| Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET Apalutamide, Androgen receptor (AR) inhibitor - High Risk Prostate Cancer | Phase 2 | Recruiting | Marco Oderda | 94 | 2024-11-25 | 2025-01-06 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Terminated | University of Washington | 8 | 2024-05-23 | 2026-10-19 |
| Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial Apalutamide, Biospecimen Collection, Computed Tomography - Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 95 | 2024-03-28 | 2026-07-17 |
| Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc AR Blockade, Carotuximab - Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Edwin Posadas, MD | 116 | 2023-12-27 | 2026-10-05 |
| Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment apalutamide, androgen deprivation therapy, cytoreductive radical prostatectomy with/without pelvic lymph node dissection - Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer | Phase 2 | Not yet recruiting | Fudan University | 47 | 2023-05-01 | 2023-02-08 |
| TherApeutics in Early ProState Cancer (TAPS02) Apalutamide Oral Tablet [Erleada], Placebo - Prostate Cancer | Phase 2 | Recruiting | Cambridge University Hospitals NHS Foundation Trust | 90 | 2023-04-24 | 2025-06-20 |
| Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) Apalutamide 60mg Tab, Androgen deprivation therapy(ADT) - Prostate Cancer, Biochemical Recurrence | Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 103 | 2023-04-01 | 2023-03-21 |
| Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer Abiraterone, Enzalutamide, Apalutamide - Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 26 | 2023-02-14 | 2026-09-15 |
| Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. Abiraterone acetate, Apalutamide, Enzalutamide - Metastatic Cancer, Neoplasm, Prostate | Phase 2 | Recruiting | Sun Pharmaceutical Industries Limited | 192 | 2022-08-31 | 2026-06-15 |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer AZD5305, Enzalutamide, Abiraterone Acetate - Metastatic Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 174 | 2022-06-02 | 2026-08-26 |
| Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer Leuprolide acetate, Goserelin acetate, Triptorelin acetate - Prostate Cancer | Phase 2 | Unknown | Fudan University | 160 | 2022-04-01 | 2022-03-16 |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Apalutamide, Cetrelimab - Small Cell Neuroendocrine Carcinoma, Prostate Cancer | Phase 2 | Terminated | Rahul Aggarwal | 2 | 2022-03-16 | 2025-05-15 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2026-11-10 |
| Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab - Prostate Cancer | Phase 2 | Recruiting | University of British Columbia | 315 | 2021-09-21 | 2026-08-14 |
Showing 20 of 61. Sign in to see all of them.
Prostatic Neoplasms (49) · Neoplasm Metastasis (3) · Prostatic Neoplasms, Castration-Resistant (2) · Adenocarcinoma (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma, Small Cell (1) · Hematologic Neoplasms (1) · Neoplasms (1) · Salivary Gland Neoplasms (1) · Small Cell Lung Carcinoma (1)
M.D. Anderson Cancer Center (7) · Dana-Farber Cancer Institute (3) · University of Washington (3) · Aragon Pharmaceuticals, Inc. (2) · Fudan University (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Janssen Research & Development, LLC (2) · Jonsson Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2) · VA Office of Research and Development (2) · Andrew J. Armstrong, MD (1) · Anhui Medical University (1) · AstraZeneca (1) · CCTU- Cancer Theme (1)
United States (41) · China (6) · United Kingdom (4) · Belgium (2) · Brazil (2) · Canada (2) · Italy (2) · Australia (1) · Austria (1) · Finland (1) · France (1) · Germany (1) · Japan (1) · Singapore (1) · Switzerland (1)
Amar Kishan (2) · Jingsong Zhang, MD, PhD (2) · Michael Schweizer (2) · Rahul Aggarwal, MD (2) · Abhishek Solanki, MD MS (1) · Ana Aparicio (1) · Bagi Jana, MD (1) · Christopher Logothetis (1) · Daniel J. George, MD (1) · Dingwei Ye, Doctoral (1) · Diogo A Bastos, MD (1) · Edwin Posadas, MD FACP (1) · Eleni Efstathiou (1)
PMID 27068431, PMID 27160947, PMID 28633425, PMID 29384722, PMID 29606109, PMID 29723398, PMID 29740894, PMID 30935383, PMID 31122212, PMID 32356465, PMID 33683939, PMID 34655838, PMID 35091711, PMID 36000794, PMID 36055231, PMID 36472728, PMID 38161319, PMID 38421243, PMID 38421252, PMID 38494380, PMID 38796422, PMID 38824003, PMID 39036382, PMID 39074346, PMID 39088398, PMID 39293393, PMID 39643549, PMID 39804646, PMID 39857987, PMID 40177596, PMID 40387589, PMID 40677104, PMID 40693904, PMID 41062343, PMID 41202201, PMID 41228234, PMID 41296089, PMID 41529384, PMID 41623173, PMID 41625480, PMID 41651176, PMID 41779146, PMID 42117295, PMID 42186347, PMID 42252348
2016 (2), 2017 (2), P30CA015704 (2), 2023 (1), I01CX002277 (1), P30CA023074 (1), P30CA072720 (1), R01CA286127 (1), R01CA300454 (1), U10CA180868 (1), UG1CA242596 (1)